OrgaNova TRiCBiO Founded to Commercialize Organoid 2.0 Technology Platform

OrgaNova TRiCBiO was officially founded to translate decades of landmark organoid biology research into a scalable, commercially available preclinical platform for the global pharmaceutical industry.

The company's founding is grounded in a series of landmark publications beginning with the 2009 Nature Medicine paper on stem cell organoid culture, the 2018 Cell paper demonstrating complete tumor microenvironment preservation (1,400+ citations), and the naming of "Organoid 2.0" in Nature Reviews Cancer in 2019.

"We spent 15 years building the science. We founded OrgaNova to put it to work," said Xingnan Li, PhD, the inventor of the ALI-PDO™ technology and Co-Founder. "The 97% failure rate in oncology drug development is not inevitable. It is a consequence of inadequate models. We are changing that."

The company is headquartered in Nanjing, China, with R&D operations and a growing international presence.